Skip to main content

Table 2 Psychotropic medication

From: Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden

 

ATCa

Study populationb

N (%)

Dementia diagnosesc

P-value

Clinical signsdof DLB

P-value

Age groupse

P-value

Yes

N (%)

No

N (%)

 

0–1

N (%)

2–4

N (%)

 

≤85 years

N (%)

≥86 years

N (%)

 

Antipsychotics

 Any

N05A

132 (21.6)

102 (23.2)

29 (18.8)

 

93 (19.1)

39 (31.5)

*

71 (27.4)

61 (17.4)

**

 Haloperidol

 

42 (7.1)

28 (6.6)

14 (9.3)

 

25 (5.3)

17 (14.3)

**

23 (9.3)

19 (5.5)

 

 Risperidone

 

57 (9.6)

49 (11.5)

8 (5.3)

 

45 (9.5)

12 (10.1)

 

29 (11.7)

28 (8.1)

 

 Other f

 

11 (1.9)

9 (2.1)

2 (1.3)

 

7 (1.5)

4 (3.4)

 

6 (2.4)

5 (1.5)

 

Anxiolytics

 Any

N05B

336 (58.4)

263 (61.7)

73 (49.0)

*

251 (54.8)

85 (72.6)

***

136 (56.2)

200 (60.1)

 

 Oxazepam

 

308 (53.6)

248 (58.2)

60 (40.3)

**

228 (49.8)

80 (68.4)

***

125 (51.7)

183 (55.0)

 

 Diazepam

 

44 (7.7)

31 (7.3)

13 (8.7)

 

25 (5.5)

19 (16.2)

***

22 (9.1)

22 (6.6)

 

Hypnotics/sedatives

 Any

N05C

234 (40.7)

176 (41.3)

58 (38.9)

 

186 (40.6)

48 (41.0)

 

103 (42.6)

131 (39.3)

 

 Zopiclone

 

189 (32.9)

139 (32.6)

50 (33.6)

 

145 (31.7)

44 (37.6)

 

78 (32.2)

111 (33.3)

 

 Other g

 

77 (13.4)

67 (15.7)

10 (6.7)

**

68 (14.8)

9 (7.7)

**

39 (16.1)

38 (11.1)

 

Anti-depressants

 Any

N06A

290 (50.4)

225 (52.8)

65 (43.6)

**

233 (48.4)

57 (60.6)

*

129 (53.3)

161 (48.3)

 

 SSRI

 

204 (35.5)

156 (36.6)

48 (32.2)

 

157 (34.3)

47 (40.2)

 

88 (36.4)

116 (34.8)

 

 Mirtazapine

 

127 (22.1)

103 (24.2)

24 (16.1)

*

99 (20.6)

28 (29.8)

 

58 (24.0)

69 (20.7)

 

 Venlafaxine

 

18 (3.1)

14 (3.3)

4 (2.7)

 

15 (3.1)

3 (3.2)

 

13 (5.4)

5 (1.5)

*

 Other

 

6 (1.0)

4 (0.9)

2 (1.3)

 

4 (0.9)

2 (1.3)

 

2 (0.8)

4 (1.2)

 
  1. aAnatomical Therapeutic Chemical (ATC) Classification System
  2. bAll participants: 610 (100%), with registered medical lists for 575 (94%) participants
  3. cDementia diagnoses: there were (N = 440) with a dementia diagnosis and (N = 154)participants without a dementia diagnosis
  4. dClinical signs: visual hallucinations, fluctuating cognition, parkinsonism and REM sleep behaviour disorder
  5. eAge group total 610 (100%): ≤85 years (N = 259) and ≥86 years (N = 351)
  6. fOther (N05A): Clozapine (n = 1), Olanzapine (n = 8), Quetiapine (n = 2)
  7. gOther (N05C): Melatonine (n = 21), Klometiazol (n = 58), Nitrazepam (n = 6), Propriomazin (n = 5)
  8. *P-value < 0.05, **P-value< 0.005, ***P-value < 0.001